Why Amgen Inc. (AMGN) Is One of the Best Cheap Stocks to Buy for 2025?
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
FiercePharma1d
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
GlobalData on MSN4d
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
Why Is Amgen Inc. (AMGN) Among Louis Navellier’s Top Long-term Stock Picks?
We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this article, we are going to take a ...
Amgen’s $1 billion expansion in Holly Springs includes 12 apprentices from Wake Tech
Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)
Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...
Amgen announces FDA approval of Lumakras in combination with Vectibix
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS ...
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...
Amgen: Growth Potential Met By High Debt Levels
Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain.
Piper Sandler maintains Amgen stock Overweight with $310 target
Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...